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Abstract
Background: A beneficial effect of regional anesthesia on cancer related outcome in various solid tumors has been
proposed. The data on prostate cancer is conflicting and reports on long-term cancer specific survival are lacking.
Methods: In a retrospective, single-center study, outcomes of 148 consecutive patients with locally advanced
prostate cancer pT3/4 who underwent retropubic radical prostatectomy (RRP) with general anesthesia combined with
intra- and postoperative epidural analgesia (n=67) or with postoperative ketorolac-morphine analgesia (n=81) were
reviewed. The median observation time was 14.00 years (range 10.87-17.75 yrs). Biochemical recurrence (BCR)-
free, local and distant recurrence-free, cancer-specific, and overall survival were estimated using the Kaplan-Meier
technique. Multivariate Cox proportional-hazards regression models were used to analyze clinicopathologic variables
associated with disease progression and death.
Results: The survival estimates for BCR-free, local and distant recurrence-free, cancer-specific survival and overall
survival did not differ between the two groups (P=0.64, P=0.75, P=0.18, P=0.32 and P=0.07). For both groups, higher
preoperative PSA (hazard ratio (HR) 1.02, 95% confidence interval (CI) 1.01-1.02, P<0.0001), increased specimen
Gleason score (HR 1.24, 95% CI 1.06-1.46, P=0.007) and positive nodal status (HR 1.66, 95% CI 1.03-2.67, P=0.04)
were associated with higher risk of BCR. Increased specimen Gleason score predicted death from prostate cancer
(HR 2.46, 95% CI 1.65-3.68, P<0.0001).
Conclusions: General anaesthesia combined with epidural analgesia did not reduce the risk of cancer progression
or improve survival after RRP for prostate cancer in this group of patients at high risk for disease progression with a
median observation time of 14.00 yrs.
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Introduction
Interest has arisen on the potential effect of the anaesthetic
technique applied during surgery for cancer on oncological
outcome. This hypothesis is intriguing and based on the fact
that not only the surgery itself but also the anaesthetic
technique and the drugs applied (especially opioids) may affect
the hosts’ immune response and consequently influence
oncological outcome after surgery [1]. Results of recent studies
addressing the potential impact of the epidural analgesia or
anaesthetic technique applied during major oncological surgery
on disease-specific outcome are ambivalent, either showing no
difference, a reduced risk of recurrence or metastases during
the initial follow up or improved survival for the first 1.5 years
with no difference thereafter in favour of combined general
anaesthesia with regional analgesia [2–4].
In prostate cancer 4 retrospective studies have been
published. Biki et al. observed a positive effect of the thoracic
epidural analgesia on biochemical recurrence (BCR)-free
survival, however cancer–specific and overall survival were not
assessed [5]. In a recent study from our institution we observed
a significant effect of epidural analgesia on clinical progression-







































free survival but not on BCR-free, cancer-specific or overall
survival [6]. Tsui et al. performed a secondary analysis in a
patient population initially randomised to either general
anaesthesia or combined anaesthesia to assess pain control.
They were unable to detect a difference in BCR-free survival
between the 2 groups [7]. Forget et al. found no association
between peridural analgesia and BCR in more than 1000
patients with localized prostate cancer cT1-2 [8].
Based on the available literature the effect of anaesthesia
technique on oncological outcome is most likely discrete.
Prostate cancer, especially organ confined prostate cancer,
generally has a relatively benign course of disease with
excellent long term survival rates. To observe a difference a
very long observation time is necessary.
In an attempt to circumvent these limitations, we chose a
subgroup of patients who underwent a standardised surgical
procedure for prostate cancer under general anaesthesia either
combined with intra- and postoperative thoracic epidural
analgesia (TEA) or with postoperative i.v. ketorolac and
morphine for analgesia and were found to have locally
advanced disease in the specimen. These patients were
therefore at high risk for rapid disease progression and all had
undergone surgery at least 10 years ago giving us the
opportunity to evaluate long term outcome and survival.
Patients and Methods
The Institutional Review Board (Department Teaching and
Research of the University Hospital, Bern) and Ethics
Committee (Kantonale Ethik Kommission Bern, Switzerland)
approved the retrospective review of the medical records of all
patients who underwent open radical retropubic prostatectomy
(RRP) in the Department of Urology of the University Hospital,
Bern between January 1994 and December 2000 and waived
Figure 1.  Biochemical recurrence-free survival of 81 patients given general anaesthesia with ketorolac-morphine
analgesia and of 67 patients given combined general anaesthesia and thoracic epidural analgesia: Kaplan-Meier estimate
with 95% confidence interval (upper and lower curves), with slash marks representing censored values (P=0.5225).  
doi: 10.1371/journal.pone.0072873.g001
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the necessity for specific informed consent from each
participant for this analysis.
Only patients with pathological locally advanced prostate
cancer stage pT3/4 who had undergone the same standardised
RRP with pelvic lymph nodes dissection (PLND) were included
in this analysis [9–11]. Patients who received neoadjuvant or
adjuvant radiotherapy or androgen deprivation treatment (ADT)
were excluded. ADT or radiotherapy was only delivered in case
of clinical progression or a short PSA doubling time (< 9 mos).
All patients underwent the same general anaesthesia,
including induction with thiopenthal (2-3 mg/kg), fentanyl (2 µg/
kg), rocuronium (0.1 mg/kg) or atracurium (0.5 mg/kg).
Anaesthesia was maintained with nitrous oxide and isoflurane.
The patients were divided into two groups: patients who
underwent combined general anaesthesia with intra- and
postoperative thoracic epidural analgesia (TEA) (n=67) and
patients given general anaesthesia alone with postoperative i.v.
ketorolac and morphine for analgesia (n=81).
TEA was activated at the beginning of RRP with bupivacaine
0.25% at a rate of 8-10ml/h. Patients with TEA received no
COX-inhibitors intraoperatively. For postoperative epidural
analgesia a standard solution containing 0.1% bupivacaine
combined with 2 µg/ml epinephrine and 2 µg/ml fentanyl was
administered at a rate of 8 to 15 ml/h for at least 48 hours after
surgery. In addition 1000mg paracetamol i.v. was given every 6
hours. No COX-inhibitors were administrated in the group
general anaesthesia/TEA analgesia postoperatively. None of
these patients required supplemental systemic administration
of morphine.
Patients without TEA received fentanyl boluses of 1-2 µg/kg
intraoperatively at the discretion of the anaesthesiologist.
Standard postoperative analgesia consisted of 30 mg ketorolac
i.v. eight hourly and 1000 mg paracetamol i.v. six hourly during
48 hours. The first dose of ketorolac was administered at the
time of fascial closure. Morphine 2 mg i.v. was given on
request to supplement analgesia if necessary.
Evaluated baseline characteristics were age, American
Society of Anesthesiologists (ASA) physical status
classification, perioperative blood transfusions, total
intraoperative dose of fentanyl, preoperative PSA, specimen
Gleason score, surgical margins status and nodal (pN) status
(according to the TNM classification 2002).
The two groups were compared for potential baseline
confounders using chi square test for categorical variables and
Figure 2.  Prostate cancer-specific survival of 81 patients given general anaesthesia with ketorolac-morphine analgesia
and of 67 patients given combined general anaesthesia and thoracic epidural analgesia: Kaplan-Meier estimate with 95%
confidence interval (upper and lower curves), with slash marks representing censored (P=0.6834).  
doi: 10.1371/journal.pone.0072873.g002
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Wilcoxon rank sum test for continuous variables. A PSA value
≥ 0.2ng/ml was considered as BCR. BCR-free survival was
calculated from operation to BCR or death, local recurrence-
free and distant recurrence-free survival from operation to local
or distant clinical progression or death resp, cancer-specific
survival from operation to death due to tumour, and overall
survival from operation to death of any cause. Patients were
censored at the time of the last urological follow-up or death
not due to events of interest. The endpoints were calculated
using the Kaplan-Meier method.
To take into account potential confounding effects,
multivariate Cox regression of each endpoint on analgesia
group and all baseline characteristics was performed. As a
supportive analysis, the endpoints were also compared
between analgesia groups using univariate Cox regression in
patients matched by propensity score, which was defined as
the probability of receiving general anaesthesia with TEA,
predicted from all baseline variables and calculated for each
patient using logistic regression. The significance level for all
parameters was 0.05. Due to the exploratory nature, no
correction for multiple testing was applied. Statistical analysis






and TEA (n=67) P Value
Age (yrs) 63.83 [59.12-67.48] 63.61 [57.61-68.17] 0.52*
Preoperative PSA
(ng/ml) 13.7 [10-21.2] 17.2 [9.2-31] 0.12*
Fentanyl (mg) 0.7 [0.5-0.75] 0.5 [0.4-0.65] 0.06*
ASA physical status    
I 21 (26) 12 (18) 0.04ǂ
II 45 (56) 50 (75)  
III 15 (18) 5 (7)  
pT3a 37 (46%) 25 (37%) 0.30
pT3b 42 (52%) 37 (55%)  
pT4 2 (2%) 5 (8%)  
Positive Nodal Status
(pN) 35 (43) 30 (45) 0.85ǂ
Specimen Gleason
score (categorical)    
<7 30 (37) 36 (5) 0.13ǂ
7 29 (36) 18 (27)  
>7 22 (27) 13 (19)  
Need for Blood
Transfusion 12 (15) 11 (16) 0.79ǂ
Need for ADT for
recurrence 39 (48) 30 (45) 0.51ǂ
Need for Radiotherapy
for recurrence 20 (25) 13 (19) 0.69ǂ
Positive Surgical
Margin 46 (57) 41 (61) 0.59ǂ
Data reported as number (%) and median [first-third quartile]. After matching the
TEA group was the same as before matching. *: P values obtained from Wilcoxon
rank sum test. ǂ: P values obtained from chi-square test. ASA=American Society of
Anesthesiologists; PSA=prostate-specific antigen
was performed in collaboration with the Institute of
Mathematical Statistics and Actuarial Science of the University
of Berne using SPSS software version 18.0 (SPSS Inc.,
Chicago, Illinois, USA), SAS version 9.2 (SAS Institute Inc.,
Cary, NC, USA) and R software version 2.4.1 (The R
Foundation for Statistical Computing, Vienna, Austria).
Results
One hundred forty eight consecutive patients (median age 64
yrs, range: 45-75 yrs) were finally included. There was no
statistically significant difference between the general
anaesthesia/TEA (n=67) and general anaesthesia/i.v.
analgesia (n=81) groups regarding baseline parameters with
the exception of ASA physical status (P=0.04) (Table 1). After
matching by propensity score, no significant difference
between the groups could be detected in 67 matched pairs.
Median intravenous morphine administration in the general
anaesthesia/i.v. analgesia was 10mg [range 6-25mg] during
the first 48 h postoperative.
The median observation time was 14.0 yrs (range 10.9-17.8
yrs). After a median follow up of 11.3 yrs (range 1.2-16.5 yrs),
45/148 (30%) patients had died: 22/67 (33%) in the general
anaesthesia/TEA group and 23/81 (28%) in the general
anaesthesia/i.v. analgesia group (P=0.54). The cause of death
was prostate cancer related in 32/148 (22%) patients: 14/67
(21%) general anaesthesia/TEA group and 18/81 (22%) in the
general anaesthesia/i.v. analgesia group (P=0.68). In 13/148
(9%) patients death was not related to prostate cancer.
BCR-free survival at 5 years was 33% (95% confidence
interval (CI): 22%-44%) for the general anaesthesia/TEA group
and 32% (95% CI: 22%-43%) for the general anaesthesia/i.v.
analgesia group, at 10 years it was 18% (95% CI: 10%-28%)
and 21% (95% CI: 12%-30%), respectively (Figure 1). The
respective cancer-specific survival was 89% (95% CI:
Table 2. Cox regression of BCR free survival.
 
Hazard Ratio (95%CI) for
BCR or Death P Value
Multivariate analysis before matching   
Anaesthesia with TEA vs. Anaesthesia
with iv Analgesia 0.91 (0.62-1.34) 0.6414
Age (yrs) 1.01 (0.98-1.05) 0.4133
ASA Classification 1.00 (0.73-1.38) 0.9830
Preoperative PSA (ng.ml-1) 1.02 (1.01-1.02) <.0001
Lymph nodes   
Positive vs. Negative 1.66 (1.03-2.67) 0.0372
Specimen Gleason score* 1.24 (1.06-1.46) 0.0073
Fentanyl (mg) 1.67 (0.82-3.39) 0.1562
Transfusion   
Yes vs. No 0.68 (0.40-1.16) 0.1540
Surgical margin   
Positive vs. Negative 1.25 (0.84-1.86) 0.2734
Univariate analysis after matching   
Anaesthesia with TEA vs. Anaesthesia
with iv Analgesia 1.00 (0.69-1.47) 0.9851
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78%-95%) and 88% (95% CI: 79%-94%) at 5 years and 79%
(95% CI: 66%-87%) and 78% (95% CI: 67%-86%) at 10 years
(Figure 2); overall survival at 5 years was 82% (95% CI:
71%-89%) for the general anaesthesia/TEA group and 85%
(95% CI: 75%-91%) for the general anaesthesia/i.v. analgesia
group, at 10 years it was 69% (95% CI: 56%-78%) and 71%
(95% CI: 60%-80%), respectively (Figure 3).
The survival estimates for BCR-free survival, local
recurrence-free survival, distant recurrence–free survival,
cancer-specific survival and overall survival did not differ
between the two groups in multivariate analysis in all patients
Table 3. Cox regression for local recurrence-free survival.
 
Hazard Ratio (95%CI) for
BCR or Death P Value
Multivariate analysis before matching   
Anaesthesia with TEA vs. Anaesthesia
with iv Analgesia 1.19 (0.41-3.43) 0.7515
Age (yrs) 0.98 (0.90-1.07) 0.6441
ASA Classification 1.64 (0.71-3.76) 0.2466
Preoperative PSA (ng.ml-1) 0.98 (0.94-1.01) 0.2024
Lymph nodes   
Positive vs. Negative 1.12 (0.33-3.74) 0.8592
Specimen Gleason score* 1.33 (0.87-2.03) 0.1913
Fentanyl (mg) 1.91 (0.31-11.80) 0.4849
Transfusion   
Yes vs. No 1.10 (0.30-4.04) 0.8851
Surgical margin   
Positive vs. Negative 1.49 (0.48-4.64) 0.4887
Univariate analysis after matching   
Anaesthesia with TEA vs. Anaesthesia
with iv Analgesia 1.16 (0.41-3.29) 0.7740
Table 4. Cox regression for distant recurrence-free survival.
 
Hazard Ratio (95%CI)
for distant recurrenceP Value
Multivariate analysis before matching   
Anaesthesia with TEA vs. Anaesthesia with
iv Analgesia 0.58 (0.27-1.29) 0.1816
Age (year) 0.98 (0.92-1.04) 0.4979
ASA* 0.96 (0.55-1.69) 0.8886
Preoperative PSA (ng/ml) 1.00 (0.99-1.01) 0.7711
Lymph nodes   
Positive vs. Negative 3.45 (1.25-9.53) 0.0169
Specimen Gleason score* 1.41 (1.00-1.98) 0.0485
Fentanyl (mg) 1.03 (0.24-4.45) 0.9670
Transfusion   
Yes vs. No 1.25 (0.47-3.32) 0.6611
Surgical margin   
Positive vs. Negative 1.15 (0.50-2.65) 0.7481
Univariate analysis after matching   
Anaesthesia with TEA vs. Anaesthesia with
iv Analgesia 0.56 (0.26-1.25) 0.1573
or in univariate analysis in matched patients (Tables 2, 3, 4, 5,
6).
Associated with higher risk for BCR were preoperative PSA
(HR 1.02, 95% CI: 1.01-1.02, P<0.0001), specimen Gleason
score (HR 1.24, 95% CI: 1.06-1.46, P=0.007), positive nodal
status (HR 1.66, 95% CI: 1.03-2.67, P=0.04) (Table 2). The
specimen Gleason score was a significant negative predictor
for distant recurrence-free survival (HR: 1.41, 95% CI:
1.00-1.98, P=0.04) (Table 4), for cancer-specific survival (HR
2.46, 95% CI: 1.65-3.68, P<0.0001) (Table 5) and for overall
survival (HR 1.85, 95% CI: 1.38-2.48, P<0.0001) (Table 6).
Positive lymph node status was a negative predictor for distant
recurrence-free survival (HR: 3.45, 95% CI: 1.25-9.53, P=0.01).
Discussion
We report that epidural analgesia combined with general
anaesthesia for radical prostatectomy did not improve BCR-
free survival, cancer recurrence and survival in patients with
locally advanced prostate cancer pT3/4 after a median
observation time of 14 years.
This contrasts with 2 recently published studies including our
prior publication, reporting that combined neuroaxial analgesia
and general anaesthesia may be associated with a reduced
risk of recurrence in prostate cancer [5,6]. In line with our
observation Tsui et al. found no difference between the groups
for biochemical recurrence-free survival in a secondary
analysis of patients randomised to either general anaesthesia
alone or combined general anaesthesia/epidural analgesia to
evaluate pain control, blood loss, and the need for blood
transfusion [7].
In the first study on this subject published by Biki et al., a
difference in BCR-free survival was reported with better
outcome in the patients with combined general anaesthesia/
epidural analgesia. Although a sign of disease persistence or
recurrence BCR-free survival is of questionable interest to the
patient as it does not translate into cancer specific survival
[12,13]. Additional treatment, such as androgen deprivation or
radiotherapy can influence BCR and are not mentioned. The
study of Biki et al. has some further limitations: the anaesthetic
regimen was determined by the anaesthetist and was neither
randomised nor consecutive patient groups. Most importantly,
oncologically relevant information is lacking such as
pathological tumor stage and the surgical technique is not
mentioned.
In the retrospective study by Forget et al., they suggest that
epidural analgesia did not influence BCR, but the use of
sufentanil increased the risk of BCR [8]. However, the
population analysed was heterogeneous, with many different
and overlapping anaesthetic regimen, a short follow-up
(median 38 months) and included patients receiving adjuvant
therapies. In addition, another limitation is the very small
number of patients not receiving systemic administration of
sufentanil. Moreover sufentanil was added in the epidural
mixture and a systemic effect cannot be ruled out and no
information is given if the epidural analgesia was activated
intraoperatively.
Epidural Analgesia and Cancer Related Outcome
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In the previous study from our institution on two consecutive
patients groups a significant difference in clinical progression
free survival was observed in favour of combined anaesthesia.
However, no difference was found in BCR-free, cancer specific
or overall survival [6].
Prostate cancer is a relatively benign disease and cancer
specific survival estimates in organ confined prostate cancer
are >95% at 10 years [14]. Therefore, hypothetically evaluation
of more aggressive disease would be necessary to observe a
difference in cancer specific survival and OS, which are the
most relevant factors for the patient. Patients with
pathologically proven non organ confined disease are at high
risk of rapid disease progression. Reported BCR and cancer
specific survival rates at 10 and 15 years are approximately
40% and 60% and 63-90% and 25-79%, respectively [15,16].
Outcome in our patients is in line with the reported literature
confirming the representativeness of our cohort. One of the
strengths of our study cohort is the uniform treatment: Surgery
and PLND were performed in a standardized technique and
none of the patients received adjuvant hormonal treatment or
radiotherapy unless their PSA doubling time was <1 year or
metastases were proven.
This may at least in part explain the difference seen in
clinical progression free survival in this and the previous study.
Patients with a rapid PSA recurrence are more likely to receive
additional therapy based on their PSA which may interfere with
the clinical course or explain the difference to the previous
study also including patients with organ confined disease. ADT
was not our endpoint. In a previous study on breast cancer a
similar observation was made with a decrease in progression
with combined anaesthesia [3].
The basis behind these observations is the potential effect of
drugs on cancer outcome. Intraoperatively administrated
fentanyl is purported to have a dose dependent effect on
immune suppression [17]. Although in our study more fentanyl
was given to patients not receiving epidural analgesia, we
Figure 3.  Overall survival of 81 patients given general anaesthesia with ketorolac-morphine analgesia and of 67 patients
given combined general anaesthesia and thoracic epidural analgesia: Kaplan-Meier estimate with 95% confidence interval
(upper and lower curves), with slash marks representing censored values (P=0.7459).  
doi: 10.1371/journal.pone.0072873.g003
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could not demonstrate a negative effect of the fentanyl dosage
on survival.
Ketorolac, by contrast, may reduce cancer progression
based on the over-expression of the COX-2 enzyme in prostate
cancer cells compared with normal or benign hypertrophied
cells. It is also associated with increased angiogenesis and
proliferation in the animal model. Mean levels of COX-2 mRNA
were shown to be 3.4-fold higher in prostate cancer tissue
compared with the paired benign tissue in an in-vivo study [18].
COX-2 inhibitors induce apoptosis in prostate cancer cell lines
[19,20]. The chemotherapeutic agent that has been studied
Table 5. Cox regression of cancer specific survival.
 
Hazard Ratio (95%CI)for
Cancer Specific Death p Value
Multivariate analysis before matching   
Anaesthesia with TEA vs. Anaesthesia
with iv Analgesia 1.51 (0.70-3.42) 0.3198
Age (yrs) 0.96 (0.19-1.05) 0.4755
ASA Classification 0.91 (0.52-1.58) 0.7298
Preoperative PSA (ng.ml-1) 1.00 (0.99-1.01) 0.9477
Lymph nodes   
Positive vs. Negative 2.94 (0.97-8.98) 0.0560
Specimen Gleason Score* 2.46 (1.65-3.68) <0.0001
Fentanyl (mg) 1.79 (0.43-7.53) 0.4265
Transfusion   
Yes vs. No 1.29 (0.43-3.91) 0.6526
Surgical Margin   
Positive vs. Negative 1.07 (0.41-2.81) 0.8874
Univariate analysis after matching   
Anaesthesia with TEA vs. Anaesthesia
with iv Analgesia 0.96 (0.45-2.05) 0.9248
Table 6. Cox regression of overall survival.
 
Hazard Ratio (95%CI)for
Any Death P Value
Multivariate analysis before matching   
Anaesthesia with TEA vs. Anaesthesia
with iv Analgesia 1.79 (0.95-3.39) 0.0710
Age (yrs) 1.01 (0.96-1.07) 0.6772
ASA Classification 0.99 (0.62-1.60) 0.9725
Preoperative PSA (ng.ml-1) 1.00 (0.99-1.01) 0.6116
Lymph nodes   
Positive vs. Negative 1.50 (0.70-3.22) 0.2993
Specimen Gleason score* 1.85 (1.38-2.48) <0.0001
Fentanyl (mg) 1.31 (0.40-4.29) 0.6537
Transfusion   
Yes vs. No 1.01 (0.42-2.46) 0.9808
Surgical margin   
Positive vs. Negative 1.23 (0.60-2.50) 0.5694
Univariate analysis after matching   
Anaesthesia with TEA vs. Anaesthesia
with iv Analgesia 1.17 (0.63-2.17) 0.6105
most extensively in cancer is celecoxib. In a murine breast
cancer model, celecoxib was shown to inhibit morphine-
induced stimulation of COX-2, angiogenesis, tumor growth,
metastasis and to lower mortality without compromising
analgesia [21]. Perioperative use of COX-2 inhibitors,
therefore, may have reduced the risk of tumor metastasis [22]
and counterbalanced the negative effect of fentanyl in our
cohort. However, a recent study did not support the use of
celecoxib for patient with high risk cancer patients [23].
Other drugs which may be of relevance were applied
perioperatively in our patients. Thiopental and isoflurane were
used to induce and maintain anesthesia. Both drugs have a
suppressive effect on T-lymphocyte proliferation [24–28].
Thiopental significantly enhanced postoperative metastasis
after excision of the primary lung tumor in rats [29].
The majority of the above mentioned findings were observed
in in-vitro or in animal studies. Among the factors potentially
explaining differences between in-vitro or animal models and
clinical findings are the duration and dosage of drug application
as well as drug metabolism.
The present comparative single-centre study of consecutive
patient cohorts has limitations inherent to all retrospective
studies: it is not randomized and a selection bias cannot be
definitively ruled out. As no intergroup differences were
detected, the number of patients may not have been adequate.
The long-term observation time in conjunction with the
advanced disease stage and the consistency of our
standardized surgical and anaesthetic techniques, however,
should render this study ideal for the detection of a difference
in disease outcome due to different anaesthetic techniques.
Alternatively the effect of anaesthesia/analgesia on cancer
specific survival may be of limited clinical value if of any at all.
Large prospective randomised multicenter studies on
gynaecological, lung and colon tumors are now registered
online at ClinicalTrial.gov and will in the future help to further
clarify whether and why epidural anaesthesia/analgesia has an
effect on cancer-specific outcome in patients undergoing
surgery for cancer. However, the time needed to recruit
patients and achieve an adequate observation period for
cancer related outcome implies that results will not be
evaluable for at least another 5 years. In the meantime
retrospective studies may help to gain further insight.
Conclusions
The hypothesis that general anaesthesia with epidural
analgesia reduces the risk of cancer progression and/or
improves survival in patients undergoing RRP for high-risk and
locally advanced prostate cancer could not be confirmed in this
comparative single-center observational study despite a long-
term median minimal observation time of 10 years.
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